Myocardial perfusion imaging methods and compositions
A myocardial imaging method that is accomplished by administering one or more adenosine A 2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A 2a receptor agonist, at least one liquid carrier, and at least one co-solvent.
1. A pharmaceutical composition comprising:
a) about 400 μg of a compound which has the formula:
b) at least one liquid carrier selected from the group consisting of water, saline, a buffer, and combinations thereof,
c) at least one sodium phosphate buffer;
d) EDTA; and
e) propylene glycol in an amount of about 15% (w:v),
wherein the pH of said pharmaceutical composition is from about 6 to about 8.
2. The pharmaceutical composition of claim 1 , wherein the pH of said pharmaceutical composition is about 7.
3. The pharmaceutical composition of claim 1 , wherein at least one liquid carrier is water.
4. The pharmaceutical composition of claim 3 , wherein the water is distilled water or de-ionized water.
5. The pharmaceutical composition of claim 3 comprising 15% (w:v) propylene glycol and 100 mM phosphate buffer at pH 7 with 0.1% EDTA.
6. The pharmaceutical composition of claim 1 , wherein the at least one sodium phosphate buffer is of a concentration of about 100 mM.
7. The pharmaceutical composition of claim 1 comprising 15% (w:v) propylene glycol and 100 mM phosphate buffer at pH 7 with 0.1% EDTA.
8. A kit comprising a vessel and the pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is contained within the vessel, and wherein the vessel is formed from either type I glass or plastic.
9. The kit of claim 8 , wherein the vessel is formed from plastic.
10. A kit comprising a vessel and the pharmaceutical composition of claim 3 , wherein the pharmaceutical composition is contained within the vessel, and wherein the vessel is formed from either type I glass or plastic.
11. The kit of claim 10 , wherein the vessel is formed from plastic.
12. A method of producing coronary vasodilation comprising administering by intravenous (iv) bolus the pharmaceutical composition of claim 1 to a human in need thereof.
13. A method of producing coronary vasodilation comprising administering by intravenous (iv) bolus the pharmaceutical composition of claim 3 to a human in need thereof.
14. A method of myocardial perfusion imaging of a human in need thereof comprising administering by intravenous (iv) bolus the pharmaceutical composition of claim 1 and a radionuclide, wherein the myocardium is examined for areas of insufficient blood flow following administration the pharmaceutical composition and the radionuclide.
15. The method of claim 14 , wherein the pharmaceutical composition and the radionuclide are administered separately.
16. The method of claim 14 , wherein the pharmaceutical composition and the radionuclide are administered simultaneously.
17. The method of claim 14 , wherein administration of the pharmaceutical composition causes at least a 2.5 fold increase in coronary blood flow for less than about 5 minutes.
18. The method of claim 14 , wherein administration of the pharmaceutical composition causes at least a 2.5 fold increase in coronary blood flow for less than about 3 minutes.
19. A method of myocardial perfusion imaging of a human in need thereof comprising administering by intravenous (iv) bolus the pharmaceutical composition of claim 3 and a radionuclide, wherein the myocardium is examined for areas of insufficient blood flow following administration the pharmaceutical composition and the radionuclide.
20. The method of claim 19 , wherein the pharmaceutical composition and the radionuclide are administered separately.